Deal Watch: Valeant Increases Bid, Wrests Salix Away From Endo

23 Mar 2015
News

Executive Summary

Janssen moves into a new generation of anticoagulation with X01 buyout. Lilly obtains Phase II-ready autoimmune candidate from South Korea’s Hanmi, which partnered a cancer compound with Spectrum just a week earlier, while AstraZeneca finds a commercialization partner for Movantik in Japan’s Daiichi Sankyo.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Subjects
Deals

Related Companies

Related Deals

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS056740

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS056740

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Deal Watch: Valeant Increases Bid, Wrests Salix Away From Endo

News

Executive Summary

Related Content

AstraZeneca’s Movantik Clears FDA; Launch On Hold Pending DEA Action

Anticoagulant Maker XO1 Takes $11M In Index Ventures’ Largest Series A

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert